23andMe Files for Bankruptcy

Published MAR 24 2025

Story

Above: In this photo illustration, a 23andMe logo seen displayed on a smartphone and in the background. Image credit: Photo Illustration by Avishek Das/Contributor/SOPA Images/LightRocket via Getty Images

The Facts

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection while simultaneously announcing the immediate resignation of co-founder and Chief Executive Officer (CEO) Anne Wojcicki.
Guardian
CNN
The California-based company, which has sold testing kits across markets including the US, UK, Canada, and Europe, recently implemented severe cost-cutting measures, including laying off 40% of its workforce and halting all therapy development programs in November.
BBC News
Wsj
Financial challenges intensified after 23andMe agreed to pay $30 million to settle a lawsuit regarding a 2023 data breach that exposed the personal information of almost 7 million customers. However, DNA records remained secure according to the company.
US News & World Report
BBC News
The company secured approximately $35 million in debtor-in-possession financing to maintain operations during the sale process, while listing both assets and estimated liabilities between $100-500 million.
US News & World Report
RTE.ie
Wojcicki's latest buyout offer valued the company at approximately $11 million, representing an 84% reduction from her previous bid after her private equity partner withdrew following the board's rejection.
Reuters
Independent
Chief Financial Officer Joe Selsavage has been appointed as interim CEO, while the company's board, led by Chair Mark Jensen, determined that a court-supervised sale process would be the optimal path forward to maximize business value.
Wsj
Independent

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

This bankruptcy filing represents a strategic move to reorganize and preserve 23andMe's valuable genetic database and customer base while addressing operational challenges. The court-supervised process provides the protection and structure needed to facilitate a successful sale and ensure continued operations. The company maintains strong potential for revival given its extensive DNA testing kit sales and established global market presence.

Narrative B

23andMe's decline from a $6 billion valuation reflects fundamental business model flaws and serious privacy concerns. The one-time purchase nature of DNA testing kits failed to generate recurring revenue, while the massive data breach severely damaged customer trust and resulted in significant financial penalties. The unsuccessful pivot to drug development and subscription services further demonstrates the company's inability to establish a sustainable business model.